Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14516472 | 0.94 | TLR7 (0.70) | TLR7TLR8 | |
| SCHEMBL13721633 | 0.94 | TLR7 (0.66) | TLR7TLR8 | |
| SCHEMBL13721780 | 0.91 | TLR7 (0.73) | TLR7TLR8 | |
| SCHEMBL3979135 | 0.91 | TLR7 (0.74) | TLR7TLR8 | |
| SCHEMBL13722011 | 0.90 | TLR7 (0.70) | TLR7TLR8 | |
| SCHEMBL726782 | 0.89 | TLR7 (0.67) | TLR7TLR8 | |
| SCHEMBL13721540 | 0.89 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL3972423 | 0.88 | TLR7 (0.79) | TLR7TLR8 | |
| SCHEMBL5356610 | 0.88 | TLR7 (0.73) | TLR7TLR8 | |
| SCHEMBL14516465 | 0.88 | TLR7 (0.64) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155688-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-06-07 | — | — | US | claimed |
| EP-3298131-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | The Regents of The University of California (US) | 2018-03-28 | — | — | EP | claimed |
| WO-2016187459-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-24 | — | — | WO | claimed |
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240033348-A1 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Pulmotect, Inc. | 2024-02-01 | — | — | US | disclosed |
| US-20240002799-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-04 | — | — | US | disclosed |
| US-11826422-B2 | Methods and compositions for adaptive immune modulation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-28 | — | — | US | disclosed |
| US-11680244-B2 | Method for generating human dendritic cells for immunotherapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-20 | — | — | US | disclosed |
| EP-3294295-B1 | TLR7 AND/OR TLR8 AGONISTS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS | INST NAT SANTE RECH MED (FR) | 2021-08-04 | — | — | EP | disclosed |
| EP-3632458-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-04-08 | — | — | EP | disclosed |
| US-8709445-B2 | Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120128715-A1 | METHOD FOR STIMULATING THE IMMUNE RESPONSE OF NEWBORNS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-24 | — | — | US | disclosed |
| US-20100310606-A1 | VACCINATION WITH KILLED BUT METABOLICALLY ACTIVE (KBMA) PROTOZOANS WITH TOLL-LIKE RECEPTOR AGONISTS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2010-12-09 | — | — | US | disclosed |
| US-7560436-B2 | Methods of treating gastrointestinal inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-14 | — | — | US | disclosed |
| US-20080193468-A1 | Method for Stimulating the Immune Response of Newborns | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| US-7199131-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199131-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-04 | — | — | US | disclosed |
| WO-2006029223-A2 | METHOD FOR STIMULATING THE IMMUNE RESPONSE OF NEWBORNS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | IFNG, IFNAR1, TNF | TLR7 38/4885TLR8 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.